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Background: In patients with STEMI and multivessel disease (MVD), it is unknown whether it is safe or desirable to also treat the non-culprit vessel 
during the primary PCI procedure. We thus sought to compare the long-term outcomes of a single combined PCI procedure of the culprit and non-culprit 
lesions vs. a stage approach with culprit only PCI followed by non-culprit PCI during a 2nd procedure from the large-scale HORIZONS-AMI trial.
Methods: Of 668 pts with STEMI and MVD, a single MV intervention was performed in 275 pts whereas staged MV PCI was performed in 393 pts. 
The 3-year rates of adverse cardiac events were analyzed according to revascularization strategy.
Results: The median time interval between the first and second PCI in the staged group was 30 days (range 6.0-51 days). The two groups were well 
matched for baseline characteristics. Single MV vs. staged MV PCI was associated with higher 3-year mortality (11.9% vs. 5.5%, HR [95%CI]=2.30 
[1.33-3.99], P=0.002), cardiac mortality (6.6% vs. 2.6%, HR=2.67 [1.23-5.79], P=0.009), death or reinfarction ( 19.4% vs. 10.9%, HR=1.89 [1.26-
2.84], P=0.009), definite/probable stent thrombosis (7.0% vs. 4.0%, HR=1.83 [0.92-3.64], P=0.08), MACE (30.4% vs. 22.6%, HR=1.42 [1.05-1.92], 
P=0.02) and NACE (MACE or major non-CABG bleeding; 35.7% vs. 28.4%, HR=1.32 [1.01-1.74], P=0.04). The mortality increase with the single PCI 
approach was evident by 30 days. Multivariable analysis will be presented. 
Conclusions: In pts with STEMI requiring MV intervention, a staged deferred PCI strategy of non-culprit lesions should remain the standard 
approach.
